Brief: Shanghai Bio-Heart Biological Technology Contracts With CERC For European Clinical Trial For Iberis 2nd
Dec 29 (Reuters) - Shanghai Bio-heart Biological Technology
Co Ltd 2185.HK :
* SHANGHAI BIO-HEART BIOLOGICAL TECHNOLOGY- CONTRACTED WITH
EUROPEAN CARDIOVASCULAR RESEARCH CENTER TO CONDUCT EUROPEAN
CLINICAL TRIAL FOR IBERIS 2ND
Source text for Eikon: ID:nHKS9lZv9Z
Further company coverage: 2185.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Bio-heart Biological Technology
See all newsBrief: Shanghai Bio-Heart Biological Technology Says NMPA Approves Bioheart Bioabsorbable Drug-Eluting Stents
Brief: Shanghai Bio-Heart Biological Technology Says Iberis Rdn System Completes Registration In Vietnam
Brief: Shanghai Bio-Heart Biological Technology Says Iberis RDN System Completed Registration In Thailand
Brief: Shanghai Bio-Heart Biological Technology Says Iberis RDN System Completes Registration With MHRA In UK
Brief: Shanghai Bio-Heart Biological Technology's Controlling Shareholder Increases Shareholding